Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.
Thirty hypertensive patients treated with a drug regimen which contained a beta-receptor antagonist (either propranolol, pindolol or metoprolol) exhibited an improvement in blood pressure control when atenolol was substituted for the corresponding beta-blocker in the drug regimen. Additional benefits noted were a reduction in concomitant drug therapy and an improvement in reported side effects. Atenolol caused a significant decrease in heart rate in the group for which the mean follow-up period was 23.6 months.
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*
D011412:Propanolamines; D001262:Atenolol; D011433:Propranolol; D010869:Pindolol; D008790:Metoprolol